• Mashup Score: 0

    Open comment allows for key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication.

    Tweet Tweets with this article
    • We’re accepting comments on our draft guideline re: systemic therapy for #hepatocellularcarcinoma. Submit your feedback by September 15: https://t.co/DMcvALm79P https://t.co/ZKstIJg9oV

  • Mashup Score: 0

    AbstractBackground:. Hepatocellular carcinoma (HCC) surveillance is underutilized, with <25% of individuals with cirrhosis receiving surveillance exams as recommended. The epidemiology of cirrhosis and HCC in the United States has also shifted in recent years, but little is known about recent trends in surveillance utilization. We characterized patterns of HCC surveillance by payer, cirrhosis etiology, and calendar year in insured individuals with cirrhosis.Methods:. We conducted a retrospective cohort study of individuals with cirrhosis using claims data from Medicare, Medicaid, and private insurance plans in North Carolina. We included individuals ≥ 18 years with a first occurrence of an ICD-9/10 code for cirrhosis between January 1, 2010, and June 30, 2018. The outcome was HCC surveillance by abdominal ultrasound, CT, or MRI. We estimated 1- and 2-year cumulative incidences for HCC surveillance and assessed longitudinal adherence to surveillance by computing the proportion of time c

    Tweet Tweets with this article
    • #ICYMI: Authors study HCC surveillance by payer, #cirrhosis etiology and calendar year in insured individuals with cirrhosis and find HCC surveillance initiation after diagnosis remains low although slightly improved over time. https://t.co/qvmOYuh4Dn #HepatocellularCarcinoma https://t.co/4p0zkg1sSD